|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:brand
|
gptkb:Mavyret
|
|
gptkbp:class
|
Antiviral
|
|
gptkbp:clinical_trial
|
gptkb:ENDURANCE-1
gptkb:ENDURANCE-3
gptkb:SURVEYOR-1
gptkb:SURVEYOR-2
gptkb:SURVEYOR-3
Phase 3
|
|
gptkbp:contraindication
|
Severe liver disease
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
gptkb:Amiodarone
gptkb:St._John's_Wort
gptkb:Carbamazepine
gptkb:Rifampin
|
|
gptkbp:duration
|
8 to 12 weeks
|
|
gptkbp:effective_date
|
2017-08-30
|
|
gptkbp:events
|
Assessment for liver disease progression
Regular monitoring of liver function
HCV RNA testing
|
|
gptkbp:formulation
|
Fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mavyret
|
|
gptkbp:indication
|
gptkb:Chronic_Hepatitis_C
|
|
gptkbp:ingredients
|
gptkb:Glecaprevir
gptkb:Pibrentasvir
|
|
gptkbp:invention
|
Patent protected
|
|
gptkbp:is_a_guide_for
|
gptkb:AASLD
EASL
|
|
gptkbp:manufacturer
|
gptkb:Abb_Vie
|
|
gptkbp:market_position
|
Available
|
|
gptkbp:mechanism_of_action
|
NS3/4 A protease inhibitor
NS5 A inhibitor
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:patient_population
|
Adults
Pediatric patients over 12 years
|
|
gptkbp:previous_name
|
No
|
|
gptkbp:price
|
Varies by region
|
|
gptkbp:requires
|
gptkb:True
|
|
gptkbp:route_of_administration
|
Oral
|
|
gptkbp:safety_measures
|
Pregnancy category C
Not recommended during breastfeeding
Risk of liver injury
Risk of reactivation of Hepatitis B
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Fatigue
Headache
|
|
gptkbp:storage
|
Store at room temperature
|
|
gptkbp:treatment
|
Sustained virologic response
|
|
gptkbp:type_of_care
|
Important for treatment success
|
|
gptkbp:used_for
|
Hepatitis C treatment
|
|
gptkbp:bfsParent
|
gptkb:glecaprevir
gptkb:pibrentasvir
gptkb:Harvoni
|
|
gptkbp:bfsLayer
|
5
|